文献速递甲状腺疾病

NR1D1过表达预示甲状腺癌疾病复发

Overexpression of NR1D1 Portends Disease Recurrence in Thyroid Cancer.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

该研究探讨NR1D1在甲状腺癌中的表达模式及预后与转化意义。免疫组化显示核NR1D1表达见于甲状腺滤泡上皮来源的癌,而正常甲状腺组织及良性结节性甲状腺肿未检测到NR1D1免疫反应性。NR1D1高表达患者疾病分期更晚、有甲状腺外侵犯、淋巴血管侵犯且无复发生存期更短;体外和体内实验表明NR1D1调节影响类器官生长、失巢凋亡抵抗及甲状腺癌细胞的侵袭和迁移能力,其促侵袭作用由β-catenin/ZEB1轴调控,过表达加速异种移植瘤生长和肺转移。

要点

  • NR1D1在甲状腺滤泡上皮来源的癌中核表达,正常甲状腺和良性结节性甲状腺肿无表达。
  • NR1D1高表达患者疾病分期更晚、有甲状腺外侵犯和淋巴血管侵犯,无复发生存期更短。
  • NR1D1通过β-catenin/ZEB1轴促进甲状腺癌细胞侵袭迁移,过表达加速异种移植瘤生长和肺转移。

核心结论

  • NR1D1在恶性甲状腺肿瘤中过表达并具有预后意义,作者认为靶向NR1D1对甲状腺癌具有治疗潜力。

研究设计与样本

  • 采用免疫组化分析评估NR1D1表达并检验其与临床病理参数的相关性,同时进行体外和体内实验以阐明NR1D1的致癌作用及潜在机制。

主要发现

  • 核NR1D1表达见于甲状腺滤泡上皮来源的癌,而正常甲状腺组织和良性结节性甲状腺肿未检测到NR1D1免疫反应性。
  • NR1D1高表达患者较低表达患者疾病分期更晚、有甲状腺外侵犯、有淋巴血管侵犯且无复发生存期更短。
  • 功能获得和缺失研究显示NR1D1调节影响类器官生长、失巢凋亡抵抗以及甲状腺癌细胞的侵袭和迁移能力。
  • NR1D1的促侵袭作用由β-catenin/ZEB1轴调控。
  • NR1D1过表达在体内加速异种移植瘤生长和肺转移。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Dysregulation of circadian rhythms has been linked to cancer susceptibility. Thyroid cancer cells demonstrate altered circadian oscillations in endogenous clock transcripts. OBJECTIVE: Our previous research identified NR1D1, a component of the circadian clock, as one of the recurrence-associated genes in papillary thyroid cancer. The objective of this study was to investigate the expression pattern of NR1D1 in thyroid cancer and explore its prognostic and translational implications. METHODS: We assessed NR1D1 expression using immunohistochemical analysis and examined its correlation with clinicopathological parameters. In vitro and in vivo experiments were performed to elucidate the oncogenic roles of NR1D1 and potential mechanisms. RESULTS: Nuclear NR1D1 expression was present in thyroid follicular epithelial-derived cancers, whereas normal thyroid tissue and benign nodular goiter showed no detectable NR1D1 immunoreactivity. Patients with high expression of NR1D1 had more advanced disease stages, extrathyroidal extension, lymphovascular invasion, and shorter recurrence-free survival compared to those with low levels of NR1D1. Through gain- and loss-of-function studies, we demonstrated that NR1D1 modulation affected the growth of organoids, resistance to anoikis, and the invasive and migratory capacity of thyroid cancer cells. The invasion-promoting effect of NR1D1 was regulated by the β-catenin/ZEB1 axis. Moreover, the overexpression of NR1D1 accelerated xenograft growth and lung metastasis in vivo. CONCLUSION: NR1D1 is overexpressed in malignant thyroid tumors and has prognostic significance. Our findings suggest therapeutic potential in targeting NR1D1 for thyroid cancer.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Hsu YC, Kuo CY, Chien MN, et al. Overexpression of NR1D1 Portends Disease Recurrence in Thyroid Cancer. J Clin Endocrinol Metab. 2025. PMID: 39359072. doi:10.1210/clinem/dgae687

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。